Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial - Batran, Salah-Eddin al-; Hofheinz, Ralf-Dieter; Haag, Georg Martin; Heike, Michael; Ronellenfitsch, Ulrich; Gaiser, Timo; Schirmacher, Peter; Sievert, Mark; Mönig, Stefan Paul (The lancet. Oncology, 2016)
Gesehen am 27.10.2017